ESR1 and breast carcinoma: The ATP‐competitive inhibitor capivasertib (Truqap) (Figure 10a), in combination with fulvestrant (Faslodex, the estrogen receptor degrader) has been approved by the FDA for adult patients with breast cancer (Turner et al., 2023).